Drugs in R & D

, Volume 4, Issue 5, pp 312–319 | Cite as

Influenza Virus Vaccine Live Intranasal — MedImmune Vaccines

CAIV-T, Influenza Vaccine Live Intranasal
Adis R&D Profile


Influenza Placebo Recipient Influenza Virus Vaccine Inactivate Influenza Vaccine Tissue Culture Infectious Dose 


  1. 1.
    MedImmune Inc. FDA Approves FluMist™ First Nasal Mist Influenza Vaccine Licensed in the US. Media Release: 17 Jun 2003. Available from URL: http://www.medimmune.com
  2. 2.
    Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. Journal of the American Medical Association 282: 137–144, 14 Jul 1999PubMedCrossRefGoogle Scholar
  3. 3.
    Jackson LA, Holmes SJ, Mendelman PM. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, admin-istered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17: 1905–1909, 9 Apr 1999PubMedCrossRefGoogle Scholar
  4. 4.
    Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, coldadapted influenza vaccine in preschool-aged children. Pediatrics 110: 662–672, Oct 2002PubMedCrossRefGoogle Scholar
  5. 5.
    Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899–906, 10 Dec 1999PubMedCrossRefGoogle Scholar
  6. 6.
    Longini Jr IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 18: 1902–1909, 17 Mar 2000PubMedCrossRefGoogle Scholar
  7. 7.
    Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, in-tranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 136: 168–175, Feb 2000PubMedCrossRefGoogle Scholar
  8. 8.
    Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal in-fluenzavirus vaccine in children. New England Journal of Medicine 338: 1405–1412, 14 May 1998PubMedCrossRefGoogle Scholar
  9. 9.
    Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Diseases 181: 1133–1137, Mar 2000PubMedCrossRefGoogle Scholar
  10. 10.
    Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatric Infectious Disease Journal 20: 740–746, Aug 2001PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations